Other · developed by Novo Nordisk
NNC0642-1895 is an agent given intravenously, studied in healthy volunteers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07829406 | Phase 1 | Healthy Volunteers | Recruiting | NVO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy Volunteers
Updated Nov 8, 2026. Something wrong or missing? Report it on the NVO page.
See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVO catalysts and pipeline →